Eagle Asset Management Inc Blueprint Medicines Corp Transaction History

Eagle Asset Management Inc

  • $16.7 Billion
  • Q3 2024

A detailed history of Eagle Asset Management Inc transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Eagle Asset Management Inc holds 154,652 shares of BPMC stock, worth $13.5 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
154,652
Previous 188,867 18.12%
Holding current value
$13.5 Million
Previous $20.4 Million 29.76%
% of portfolio
0.09%
Previous 0.11%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$84.1 - $120.5 $2.88 Million - $4.12 Million
-34,215 Reduced 18.12%
154,652 $14.3 Million
Q2 2024

Aug 12, 2024
SELL
$85.18 - $108.78 $2.76 Million - $3.52 Million
-32,384 Reduced 14.64%
188,867 $20.4 Million
Q1 2024

May 09, 2024
SELL
$73.17 - $99.79 $742,309 - $1.01 Million
-10,145 Reduced 4.38%
221,251 $21 Million
Q4 2023

Feb 12, 2024
BUY
$43.96 - $92.84 $979,384 - $2.07 Million
22,279 Added 10.65%
231,396 $21.3 Million
Q3 2023

Nov 13, 2023
BUY
$46.9 - $66.0 $221,930 - $312,312
4,732 Added 2.32%
209,117 $10.5 Million
Q2 2023

Aug 09, 2023
BUY
$42.2 - $66.37 $1.68 Million - $2.64 Million
39,749 Added 24.14%
204,385 $12.9 Million
Q1 2023

May 08, 2023
SELL
$37.97 - $50.0 $561,956 - $740,000
-14,800 Reduced 8.25%
164,636 $7.41 Million
Q4 2022

Feb 14, 2023
BUY
$41.06 - $66.48 $170,563 - $276,157
4,154 Added 2.37%
179,436 $7.86 Million
Q3 2022

Nov 07, 2022
SELL
$49.93 - $77.7 $695,724 - $1.08 Million
-13,934 Reduced 7.36%
175,282 $11.5 Million
Q2 2022

Aug 10, 2022
SELL
$45.23 - $70.15 $7.59 Million - $11.8 Million
-167,813 Reduced 47.0%
189,216 $9.56 Million
Q1 2022

May 12, 2022
SELL
$54.1 - $110.08 $1.49 Million - $3.04 Million
-27,598 Reduced 7.18%
357,029 $22.8 Million
Q4 2021

Feb 11, 2022
SELL
$94.25 - $115.99 $1.19 Million - $1.46 Million
-12,602 Reduced 3.17%
384,627 $42.1 Million
Q3 2021

Nov 10, 2021
SELL
$80.98 - $109.47 $4.51 Million - $6.09 Million
-55,656 Reduced 12.29%
397,229 $40.8 Million
Q2 2021

Aug 11, 2021
SELL
$82.78 - $101.0 $970,926 - $1.18 Million
-11,729 Reduced 2.52%
452,885 $39.8 Million
Q1 2021

May 14, 2021
SELL
$90.71 - $108.28 $33,744 - $40,280
-372 Reduced 0.08%
464,614 $45.5 Million
Q4 2020

Feb 12, 2021
SELL
$92.08 - $124.48 $5.5 Million - $7.44 Million
-59,754 Reduced 11.39%
464,986 $52.1 Million
Q3 2020

Nov 12, 2020
SELL
$66.45 - $92.7 $3.04 Million - $4.24 Million
-45,757 Reduced 8.02%
524,740 $48.1 Million
Q2 2020

Aug 12, 2020
SELL
$57.09 - $79.27 $1.69 Million - $2.35 Million
-29,607 Reduced 4.93%
570,497 $43.7 Million
Q1 2020

May 11, 2020
SELL
$48.11 - $82.22 $7.91 Million - $13.5 Million
-164,476 Reduced 21.51%
600,104 $35.1 Million
Q4 2019

Feb 07, 2020
SELL
$66.73 - $82.59 $250,104 - $309,547
-3,748 Reduced 0.49%
764,580 $61.3 Million
Q3 2019

Nov 04, 2019
BUY
$72.9 - $101.41 $448,335 - $623,671
6,150 Added 0.81%
768,328 $56.4 Million
Q2 2019

Aug 05, 2019
SELL
$73.54 - $97.8 $127,224 - $169,194
-1,730 Reduced 0.23%
762,178 $71.9 Million
Q1 2019

May 01, 2019
BUY
$48.7 - $86.6 $128,519 - $228,537
2,639 Added 0.35%
763,908 $61.2 Million
Q4 2018

Feb 11, 2019
SELL
$45.57 - $74.26 $793,555 - $1.29 Million
-17,414 Reduced 2.24%
761,269 $41 Million
Q3 2018

Nov 08, 2018
BUY
$58.91 - $78.32 $37.9 Million - $50.4 Million
643,841 Added 477.48%
778,683 $60.8 Million
Q2 2018

Aug 07, 2018
BUY
$60.96 - $101.18 $8.22 Million - $13.6 Million
134,842 New
134,842 $8.56 Million

Others Institutions Holding BPMC

# of Institutions
351
Shares Held
60.3M
Call Options Held
2.25M
Put Options Held
1.18M
View Full List

About Blueprint Medicines Corp

BPMC Quotes by TradingView
  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.22B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Eagle Asset Management Inc Portfolio

Follow Eagle Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Asset Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email